CoChat

Highly Purified Eicosapentaenoic Acid Increases Interleukin-10 Levels of Peripheral Blood Monocytes in Obese Patients With Dyslipidemia

Open access
Satoh-Asahara, Noriko, Shimatsu, Akira, Sasaki, Yousuke, Nakaoka, Hidenori, Himeno, Akihiro, Tochiya, Mayu, Kono, Shigeo, Takaya, Tomohide, Ono, Koh, Wada, Hiromichi, Suganami, Takayoshi, Hasegawa, Koji, Ogawa, Yoshihiro · 2012 · Diabetes Care
Cited by 64

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: It has recently been highlighted that proinflammatory (M1) macrophages predominate over anti-inflammatory (M2) macrophages in obesity, thereby contributing to obesity-induced adipose inflammation and insulin resistance. A recent clinical trial revealed that highly purified eicosapentaenoic acid (EPA) reduces the incidence of major coronary events. In this study, we examined the effect of EPA on M1/M2-like phenotypes of peripheral blood monocytes in obese dyslipidemic patients. RESEARCH DESIGN AND METHODS: Peripheral blood monocytes were prepared from 26 obese patients without and 90 obese patients with dyslipidemia. Of the latter 90 obese patients with dyslipidemia, 82 patients were treated with or without EPA treatment (1.8 g daily) for 3 months. RESULTS: Monocytes in obese patients with dyslipidemia showed a significantly lower expression of interleukin-10 (IL-10), an M2 marker, than those without dyslipidemia. EPA significantly increased serum IL-10 and EPA levels, the EPA/arachidonic acid (AA) ratio, and monocyte IL-10 expression and decreased the pulse wave velocity (PWV), an index of arterial stiffness, compared with the control group. After EPA treatment, the serum EPA/AA ratio was significantly correlated with monocyte IL-10 expression. Only increases in monocyte IL-10 expression and serum adiponectin were independent determinants of a decreased PWV by EPA. Furthermore, EPA significantly increased the expression and secretion of IL-10 in human monocytic THP-1 cells through a peroxisome proliferator–activated receptor (PPAR)γ-dependent pathway. CONCLUSIONS: This study is the first to show that EPA increases the monocyte IL-10 expression in parallel with decrease of arterial stiffness, which may contribute to the antiatherogenic effect of EPA in obese dyslipidemic patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-0269

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 30

  1. Weisberg, 2003, Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest, 112, 1796, 10.1172/JCI200319246 · DOI · Paper page
  2. Gordon, 2005, Monocyte and macrophage heterogeneity, Nat Rev Immunol, 5, 953, 10.1038/nri1733 · DOI · Paper page
  3. Lumeng, 2007, Obesity induces a phenotypic switch in adipose tissue macrophage polarization, J Clin Invest, 117, 175, 10.1172/JCI29881 · DOI · Paper page
  4. Lumeng, 2008, Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes, Diabetes, 57, 3239, 10.2337/db08-0872 · DOI · Paper page
  5. Swirski, 2009, Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis, Arterioscler Thromb Vasc Biol, 29, 1424, 10.1161/ATVBAHA.108.180521 · DOI · Paper page
  6. Bouhlel, 2007, PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties, Cell Metab, 6, 137, 10.1016/j.cmet.2007.06.010 · DOI · Paper page
  7. Ghanim, 2004, Circulating mononuclear cells in the obese are in a proinflammatory state, Circulation, 110, 1564, 10.1161/01.CIR.0000142055.53122.FA · DOI · Paper page
  8. Satoh, 2010, Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone, Diabetes Care, 33, e7, 10.2337/dc09-1315 · DOI · Paper page
  9. Fujisaka, 2009, Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice, Diabetes, 58, 2574, 10.2337/db08-1475 · DOI · Paper page
  10. Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 · DOI · Paper page
  11. Satoh, 2007, Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome, Diabetes Care, 30, 144, 10.2337/dc06-1179 · DOI · Paper page
  12. Itoh, 2007, Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects, Arterioscler Thromb Vasc Biol, 27, 1918, 10.1161/ATVBAHA.106.136853 · DOI · Paper page
  13. Satoh, 2009, Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome, Hypertens Res, 32, 1004, 10.1038/hr.2009.145 · DOI
  14. Renier, 1993, Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice. Modulation of macrophage secretory activities, Arterioscler Thromb, 13, 1515, 10.1161/01.ATV.13.10.1515 · DOI · Paper page
  15. Michaud, 2001, Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs, Diabetes, 50, 660, 10.2337/diabetes.50.3.660 · DOI · Paper page
  16. Ueeda, 2008, Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction, Circ J, 72, 1836, 10.1253/circj.CJ-08-0249 · DOI
  17. Matsuzaki, 2009, Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease, Circ J, 73, 1283, 10.1253/circj.CJ-08-1197 · DOI · Paper page
  18. Satoh, 2008, Evaluation of the cardio-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obesity and metabolic syndrome, Hypertens Res, 31, 1921, 10.1291/hypres.31.1921 · DOI · Paper page
  19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Expert Panel on detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
  20. Manigrasso, 2005, Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss, J Clin Endocrinol Metab, 90, 5876, 10.1210/jc.2005-0281 · DOI
  21. Esposito, 2003, Association of low interleukin-10 levels with the metabolic syndrome in obese women, J Clin Endocrinol Metab, 88, 1055, 10.1210/jc.2002-021437 · DOI · Paper page
  22. Pinderski Oslund, 1999, Interleukin-10 blocks atherosclerotic events in vitro and in vivo, Arterioscler Thromb Vasc Biol, 19, 2847, 10.1161/01.ATV.19.12.2847 · DOI · Paper page
  23. Namiki, 2004, Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice, Atherosclerosis, 172, 21, 10.1016/j.atherosclerosis.2003.08.032 · DOI
  24. Han, 2010, Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice, FASEB J, 24, 2869, 10.1096/fj.09-148155 · DOI · Paper page
  25. Kawashima, 2008, Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma, Prostaglandins Leukot Essent Fatty Acids, 79, 59, 10.1016/j.plefa.2008.07.002 · DOI
  26. Thompson, 2007, Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells, Cytokine, 39, 184, 10.1016/j.cyto.2007.07.191 · DOI
  27. Matsumoto, 2008, Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice, Atherosclerosis, 197, 524, 10.1016/j.atherosclerosis.2007.07.023 · DOI
  28. Tishinsky, 2011, Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARγ-dependent manner in human adipocytes, Obesity (Silver Spring), 19, 262, 10.1038/oby.2010.186 · DOI · Paper page
  29. Kumada, 2004, Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages, Circulation, 109, 2046, 10.1161/01.CIR.0000127953.98131.ED · DOI · Paper page
  30. Lee, 2009, Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction—data from Infarction Prognosis Study (IPS) Registry, Circ J, 73, 2250, 10.1253/circj.CJ-09-0327 · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Satoh-Asahara, N., Shimatsu, A., Sasaki, Y., Nakaoka, H., Himeno, A., Tochiya, M., Kono, S., Takaya, T., Ono, K., Wada, H., Suganami, T., Hasegawa, K., & Ogawa, Y.
Venue
Diabetes Care
Published
2012-11-14
Volume
35
Issue
12
Pages
2631-2639
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2114867133
Cited by
64
References
9
FWCI
5.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.